Article Text
Statistics from Altmetric.com
QUESTION: In offspring at risk for atopic disease, does oral administration of Lactobacillus GG (LGG), given prenatally to mothers and postnatally to their infants, prevent atopic eczema?
Design
Randomised (unclear allocation concealment*), blinded (clinicians, patients, and outcome assessors),*) controlled trial with 2 years of follow up.
Setting
Antenatal clinics in Turku, Finland.
Patients
159 pregnant women who had atopic disease, or ≥ 1 first-degree relative (mother, father, or older sibling), or partner with atopic eczema, allergic rhinitis, or asthma. 132 women (83%) and 132 children completed follow up.
Intervention
Mothers were allocated to LGG (1 × 1010 colony-forming units [Valio Limited, Helsinki, Finland]) (n=77) or to placebo (microcrystalline cellulose) (n=82). The capsules were taken daily for 2 to 4 weeks before expected delivery. After delivery, …
Footnotes
-
Sources of funding: Finnish Foundation for Paediatric Research; National Technology Agency of Finland; Allergy Research Foundation in southwest Finland.
-
For correspondence: Dr M Kalliomäki, Department of Paediatrics, Turku University Hospital, P.O. Box 52, FI-20521 Turku, Finland.